miRNA composition for detecting breast cancer brain metastases and kit with same

A technology for brain metastases and breast cancer, applied in the field of medical molecular biology, can solve the problems of unknown sources, multiple influencing factors, and low abundance of miRNA expression, and achieve the effects of improving prognosis evaluation, improving accuracy, and avoiding detection errors

Inactive Publication Date: 2018-09-28
NANYANG NORMAL UNIV
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the current low sensitivity of detection of breast cancer brain metastases
Among the existing patents, the patent with the application number CN200680036598.3 discloses the detection of dozens of miRNA combinations such as miR-10b, miR-21, and miR-122 in the cancer cells of the subject to determine breast cancer Prognosis, but it does not indicate whether the detected miRNA combination is related to brain metastasis, but only to determine whether the patient has the risk of breast cancer; the patent application number CN201680076769.4 discloses that by detecting miR-181c in blood, predicting cancer brain metastasis Metastasis, but with the in-depth develop

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • miRNA composition for detecting breast cancer brain metastases and kit with same
  • miRNA composition for detecting breast cancer brain metastases and kit with same
  • miRNA composition for detecting breast cancer brain metastases and kit with same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Verification of the accuracy of miRNA small molecule marker combination in predicting brain metastasis of breast cancer

[0030] 1. Materials and methods

[0031] 1. General information

[0032]All the subjects were hospitalized patients (Han Chinese) from November 2016 to March 2018, a total of 116 cases. According to the presence or absence of brain metastases, the patients in the research group were divided into two groups: (1) breast cancer brain metastases group (research group): 48 cases, aged 25-71 years; inclusion criteria: 1) all confirmed by imaging and pathological examination Patients with breast cancer and no other systemic tumors; 2) did not receive surgery, radiotherapy and chemotherapy before cerebrospinal fluid collection; exclusion criteria: 1): exclusion of other systemic tumors, diabetes, hypertension, and cardiovascular and cerebrovascular diseases; 2) exclusion of combined autoimmunity Diseases and severe heart, lung, liver, and kidney dysfunctio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a miRNA composition for detecting breast cancer brain metastases and a kit with same. The miRNA composition comprises miR-10b and one or more of miR-200a, miR-122, miR-21 and miR-181c. The kit comprises forward and reverse primers of the miRNA composition, forward and reverse primers of an external reference U6 RNA, a cerebrospinal fluid RNA extraction system, a reverse transcription reagent, a PCR amplification reagent and a cDNA mixed positive reference product. According to the miRNA composition, a group of miRNAs are adopted as novel breast cancer brain metastases markers, low specificity and low sensitivity caused by tumor heterogeneity are hard to overcome by using a single marker can be alleviated, prognosis effectiveness evaluation of a patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed. The miRNA composition is used for preparing a kit or a biological chip for prognosis inspection on breast cancer by using a fluorescent quantitative/digital PCR method, low specificity and low sensitivity caused by tumor heterogeneity can be avoided, the prognosis effectiveness evaluation of the patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed.

Description

technical field [0001] The invention belongs to the technical field of medical molecular biology, and in particular relates to a miRNA combination for detecting brain metastasis of breast cancer and a kit containing the combination. Background technique [0002] Breast cancer is the first malignant tumor in modern women, and its death rate ranks among the top five among all cancer deaths in women for a long time. The incidence of breast cancer is still gradually increasing all over the world. According to reports, by 2015, the incidence rate accounted for about 27% of all malignant tumors in women. Breast cancer is a cancer that is more prone to brain metastases, accounting for the second place in brain metastases, accounting for about 10% to 16%. The incidence of breast cancer in my country is also increasing at a growth rate of 3%-4%, which is higher than the average level of similar diseases in the world. According to reports, about 25%-40% of breast cancer patients may...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886C12N15/113
CPCC12Q1/6886C12Q2600/158C12Q2600/178
Inventor 徐茜刘丽娜白方会阚云超其他发明人请求不公开姓名
Owner NANYANG NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products